Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417544 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Benoît Souchet und 3 weiteren Autor:innen. Beteiligte Einrichtung: AgenT SAS, 4 Rue Pierre Fontaine, 91000 Evry-Courcouronnes, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomedical Research. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) was first characterized by Dr. Alois Alzheimer in 1906 by studying a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles. Subsequent research highlighted the roles of Aβ peptides and tau proteins, which are the primary constituents of these lesions, which led to the amyloid cascade hypothesis. Technological advances, such as PET scans using Florbetapir, have made it possible to visualize amyloid plaques in living patients, thus improving AD’s risk assessment. The National Institute on Aging and the Alzheimer’s Association introduced biological diagnostic criteria in 2011, which underlined the amyloid deposits diagnostic value. However, potential confirmation bias may have led researchers to over-rely on amyloid markers independent of AD’s symptoms, despite evidence of their limited specificity. This review provides a critical examination of the current research paradigm in AD, including, in particular, the predominant focus on amyloid and tau species in diagnostics. We discuss the potential multifaceted consequences of this approach and propose strategies to mitigate its overemphasis in the development of new biomarkers. Furthermore, our study presents comprehensive guidelines aimed at enhancing the creation of biomarkers for accurately predicting AD dementia onset. These innovations are crucial for refining patient selection processes in clinical trial enrollment and for the optimization of therapeutic strategies. Overcoming confirmation bias is essential to advance the diagnosis and treatment of AD and to move towards precision medicine by incorporating a more nuanced understanding of amyloid biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AgenT SAS, 4 Rue Pierre Fontaine, 91000 Evry-Courcouronnes, France.
ORCID-Profile: Alkéos Michaïl, Baptiste Billoir, Jérôme Braudeau
Zitieren
APA
Souchet, B., Michaïl, A., Billoir, B., & Braudeau, J. (2023). Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417544
Vancouver
Souchet B, Michaïl A, Billoir B, Braudeau J. Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417544
BibTeX
@article{Souchet2023,
author = {Souchet, Benoît and Michaïl, Alkéos and Billoir, Baptiste and Braudeau, Jérôme},
title = {Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417544}
}
EUVIMED